VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Norovirus Infections
Conditions
Norovirus Infections
Trial Timeline
Dec 27, 2021 → Oct 27, 2023
NCT ID
NCT05212168About VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum
VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum is a phase 1/2 stage product being developed by Vaxart for Norovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT05212168. Target conditions include Norovirus Infections.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05212168 | Phase 1/2 | Completed |
Competing Products
11 competing products in Norovirus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN | Vaxart | Phase 1/2 | 33 |
| VXA-G1.1-NN Oral Vaccine | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN | Vaxart | Phase 1 | 25 |
| Norwalk GI.1 Virus | Vaxart | Phase 1 | 25 |
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo | Vaxart | Phase 2 | 44 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-GI.1.NN + Placebo Tablet | Vaxart | Phase 1 | 25 |
| CDI-988 + Placebo | Cocrystal Pharma | Phase 1/2 | 33 |